Drug that Targets the PDGFRA exon 18/PDGFRA D842V mutation

Blueprint Medicines

CAMBRIDGE, Mass., January 9, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. AYVAKIT is the first precision therapy approved to treat a genomically defined population of patients with GIST.  Read more…

See also Blueprint Medicines and Ayvakit (avapritinib) for more information.

Ayvakit (avapritinib)

LRG Staff
Author: LRG Staff